GENSIGHT BIOLOGICS S.A. (EPA:SIGHT) | WebDisclosure

Basculer en Français

10064	Companies
205720	Keywords
135968	Articles
109071	Press releases

Headlines Articles Press releases GENSIGHT BIOLOGICS S.A.

Home
Companies
GENSIGHT BIOLOGICS S.A.

BRIEF

published on 03/23/2026 at 09:53, 3 hours 6 minutes ago

Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital

Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF

published on 03/23/2026 at 09:53, 3 hours 6 minutes ago

Heights Capital Management dépasse 8% du capital de GENSIGHT BIOLOGICS

Franchissement De Seuil Augmentation De Capital GenSight Biologics Capital Et Droits De Vote Heights Capital
PRESS RELEASE

published on 03/23/2026 at 09:48, 3 hours 11 minutes ago

Franchissement de seuils
Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. publiée le 17 mars 2026

Déclaration Franchissement De Seuils Heights Capital Management Gensight Biologics S.A. CVI Investments
BRIEF

published on 03/18/2026 at 10:20, 5 days 2 hours ago

GenSight Biologics finalizes its €1.7 million fundraising round

Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
BRIEF

published on 03/18/2026 at 10:20, 5 days 2 hours ago

GenSight Biologics finalise sa levée de fonds de 1,7 million d'euros

Actions Ordinaires Levée De Fonds GenSight Biologics Thérapies Géniques Facteurs De Risque
PRESS RELEASE

published on 03/18/2026 at 10:15, 5 days 2 hours ago

Inside Information / Other news releases
GenSight Biologics closes nearly €1.7 million fundraising for developing gene therapies in ophthalmology and CNS disorders. Contact: CFO Jan Eryk Umiastowski

Fundraising Ophthalmology GenSight Biologics Gene Therapies CNS Disorders
PRESS RELEASE

published on 03/18/2026 at 10:15, 5 days 2 hours ago

Informations privilégiées / Autres communiqués
GenSight Biologics annonce le règlement-livraison de sa levée de fonds de 1,7 millions d’euros. La société biopharmaceutique se spécialise dans les thérapies géniques pour les maladies neurodégénératives, notamment de la rétine et du système nerveux central

Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
BRIEF

published on 03/10/2026 at 09:05, 13 days 3 hours ago

GenSight Biologics lève 1,7 million d'euros lors d'une nouvelle levée de fonds.

Stratégie Financière Essais Cliniques Thérapie Génique Collecte De Fonds Actions Et Bons De Souscription
BRIEF

published on 03/10/2026 at 09:05, 13 days 3 hours ago

GenSight Biologics Secures €1.7 Million in Fresh Fundraising

Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE

published on 03/10/2026 at 09:00, 13 days 3 hours ago

Inside Information / News release on accounts, results
GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans

Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones

Accesswire

Published on 03/23/2026 at 12:32, 27 minutes ago

Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 29 minutes ago

Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 12:30, 29 minutes ago

High Tide Resources Announces Closing of Concurrent Non-Brokered Private Placements for Gross Proceeds of $8.3 Million
Published on 03/23/2026 at 12:20, 39 minutes ago

Guanajuato Silver Adds Veteran Mine Operator to Board of Directors
Published on 03/23/2026 at 12:15, 44 minutes ago

Snipp Interactive Secures US$3 Million Contract, Largest in Company History

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 12:40, 19 minutes ago

EQS-Adhoc: Ströer plans a dividend of €1.85 for fiscal year 2025 and approves a share buyback program of up to €50 million
Published on 03/23/2026 at 12:33, 26 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 03/23/2026 at 12:29, 30 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 03/23/2026 at 11:44, 1 hour 15 minutes ago

Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
Published on 03/23/2026 at 11:30, 1 hour 29 minutes ago

EQS Group lance un module de gestion des risques pour faciliter la surveillance continue des risques liées aux données et à l’IA

Les Echos

Published on 03/23/2026 at 08:10, 4 hours 49 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 17 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 17 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE